Screen the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute has awarded a firm fixed price purchase order to Charles River Discovery Research Services UK Limited to conduct an off-target binding screen for the A10 antibody. This antibody is designed to target cancer cells with high levels of epidermal growth factor receptor, and the primary objective of this contract is to identify any unintended interactions with other plasma membrane or secreted proteins that could lead to serious side effects in patients. Managed by the Department of Health and Human Services through the Program Support Center Acquisition Management Services, the project will be performed in Saffron, Essex. The contract, identified by solicitation number 75N91026P00004, focuses on ensuring the safety and specificity of the A10 antibody before further clinical application.
General Info
Contract Value
$38,750Place of Performance
Saffron , GB-ESS, GBRSet-Aside
Award Issued Date
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This is a Firm Fixed Priced purchase order. NCI solicited and negotiated directly with Charles River Discovery Research Services UK Limited. The National Cancer Institute (NCI) has a program to use an antibody called, 'A10' to target cancer cells that have a lot of the epidermal growth factor receptor on their cell surface. While this antibody has been extensively tested and characterized it is not known if it also binds any other cell surface proteins. The contractor shall perform an off-target screen on an NCI antibody and report back on any problematic interactions that could predict a serious side effect should the antibody be given to a cancer patient. The A10 is NOT known to bind other cell surface proteins or secreted proteins but this needs to be addressed in the off-target screen.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → Program Support Center Acq Management Svc
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
